QUANTUM CYBER NV

Quantum Cyber’s CEO buys 28M shares, boosting confidence in its CRISPR‑based cyber‑defense platform amid regulatory approval and strong Phase II results.

Quantum Cyber insider buying climbs amid sharp price dip—executives buying at $1.14 signals long‑term confidence, but investors should watch revenue and regulatory risks.

Quantum Cyber NV insider option buys hint at a strategic pivot—new diagnostics or pharma partnership could spark a share rally.

Quantum Cyber’s insider buying signals a strategic shift to cybersecurity for healthcare. Discover how leadership’s stake and rebranding could unlock growth in data‑security, telehealth and value‑based care.

Quantum Cyber NV’s insider buying, tech edge, & defense contracts signal a possible turnaround despite a steep price drop—watch for the next catalyst.